US-based Strathspey Crown Holdings’ subsidiary Alphaeon has signed a co-promotion agreement with Tracey Technologies to market next-generation iTrace platform.
The company developed iTrace to measure patients’ quality of vision with patented forward ray tracing technology.
Alphaeon will be a co-exclusive sales representative with Tracey, offering the iTrace next-generation platform to ophthalmologists, within the US.
Ophthalmologists can identify internal aberrations using iTrace, and it also helps them to determine the best refractive procedure and customise lens implant for each patient.
Alphaeon CEO Robert Grant said: "iTrace is a great complement to our developing ophthalmic technology offering, integrating with TouchMD to further enhance the patient education experience.
"We believe it will be a catalyst for ophthalmologists to grow their premium, custom procedures including refractive lens exchange and Lasik."
The company intends to initiate selling the next-generation iTrace platform from this month.
Tracey Technologies CEO Joe Wakil said: "We believe diagnostic information available in the iTrace, like the new dysfunctional lens analysis, will provide Alphaeon’s customers with quality of vision tools that will improve patient care and ultimately practice performance."
Tracey develops and manufactures advanced refractive diagnostic devices ,and produces devices integrating ray tracing aberrometry wavefront analysis with advanced corneal topography analysis. The iTrace series of products has been offered since 2008.
Image: Alphaeon Corporation Headquarters, Irvine, California. Photo: courtesy of PRNewswire / ALPHAEON Corporation.